Andrew Huntley
Managing Partner, Head of Healthcare
ロンドン, ホーチミン
Andrew Huntley is a Managing Partner of BDA. Having joined the co-founders in 1998, he established and oversaw BDA’s early Asian offices including Singapore, Shanghai and Hong Kong, subsequently co-managed BDA’s New York office from 2002 to 2005, and managed its London office from 2005 to 2018.
He now travels widely in Asia and Europe from his base in Ho Chi Minh City and oversees BDA’s global Healthcare & Life Sciences sector. Mr. Huntley has advised clients on transactions across Asia as well as in Europe and North America, including both blue chip corporate clients such as Arkema, Celestica, Clariant, Edenred, Henkel, Jardine Matheson, Johnson Matthey, Laird Group, Rexel, Sumitomo Chemical, SunGard, ThomsonReuters, Tata Motors and Weir Group as well as financial sponsors such as Actis, Ardian, Bregal Capital, EQT, LDC, Investcorp, Mekong Capital, Nova Capital, Prudential, Segulah, Seera and STIC. Before BDA, Mr. Huntley worked for the Jardine Matheson Group in HK, China, Taiwan and Vietnam. He acted as the Group Representative in Vietnam and had executive responsibility for Group businesses there and in Taiwan. Mr. Huntley was educated at Oxford University (MA Hons, Chinese). He is fluent in Mandarin and conversant in Vietnamese.
Recent transactions
has been acquired by
2023
received investment from
2023
a portfolio company of
has been acquired by
2022
agreed to divest East Syracuse, New York facility to
2022
Debt and equity restructuring
2022
a portfolio company of
has been acquired by
2022
investment from
2021
has been acquired by
2021
a portfolio company of
divested 100% to
2021
a portfolio company of
divested 100% to
2021
a portfolio company of
has been acquired by
2021
raised Series B round from
2021
backed by
has been acquired by
2020
divested Escientia Life Sciences to Deccan Fine Chemicals
2020
divested significant stake in
Kehua Bio-Engineering to Gree Real Estate
2020
majority sale
2019
divested majority stake to
2019
a portfolio company of
has been acquired by
2018
a portfolio company of
has been acquired by
AGIC and Humanwell
2017
OEP Turkey Tech divested its 48.08% equity stake in
to
2017